GetTopicDetailResponse(id=e68c1265e82c, topicName=全身型重癥肌無力, introduction=, content=Inebilizumab 全身型重癥肌無力, image=null, comments=0, allHits=135, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Fri May 02 21:32:15 CST 2025, time=2025-05-02, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=445610, tagList=[TagDto(tagId=445610, tagName=全身型重癥肌無力)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2263234, encodeId=e67e2263234e7, content=<a href='/topic/show?id=a8a09831d3' target=_blank style='color:#2F92EE;'>#Inebilizumab#</a> <a href='/topic/show?id=e68c1265e82c' target=_blank style='color:#2F92EE;'>#全身型重癥肌無力#</a>, objectTitle=《新英格蘭雜志》：Inebilizumab治療全身型重癥肌無力的三期臨床試驗, objectType=article, longId=874559, objectId=f3908e4559a9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250220/1740053904413_8538692.png, objectUrl=/article/show_article.do?id=f3908e4559a9, replyNumber=0, likeNumber=27, createdTime=2025-05-02, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=f3908e4559a9, moduleTitle=《新英格蘭雜志》：Inebilizumab治療全身型重癥肌無力的三期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f3908e4559a9)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-05-02發(fā)表于陜西省
